Abstract | AIM: METHODS: Using multicenter, prospective, double-blind, parallel, placebo controlled and randomized method, 50 patients were administered orally 0.2 mg (4 tablets) Hup and 53 patients were given po 4 tablets of placebo bid for 8 wk. All patients were evaluated with Wechsler memory scale, Hasegawa dementia scale, mini-mental state examination scale, activity of daily living scale, treatment emergency symptom scale, and measured with BP, HR, ECG, EEG, ALT, AKP, BUN, Cr, Hb, WBC, and urine routine. RESULTS: About 58% (29/50) of patients treated with Hup showed improvements in their memory (P < 0.01), cognitive (P < 0.01), and behavioral (P < 0.01 functions. The efficacy of Hup was better than placebo (36%, 19/53) (P < 0.05). No severe side effect was found. CONCLUSION:
|
Authors | S S Xu, Z X Gao, Z Weng, Z M Du, W A Xu, J S Yang, M L Zhang, Z H Tong, Y S Fang, X S Chai |
Journal | Zhongguo yao li xue bao = Acta pharmacologica Sinica
(Zhongguo Yao Li Xue Bao)
Vol. 16
Issue 5
Pg. 391-5
(Sep 1995)
ISSN: 0253-9756 [Print] China |
PMID | 8701750
(Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Alkaloids
- Cholinesterase Inhibitors
- Sesquiterpenes
- Tablets
- huperzine A
|
Topics |
- Aged
- Aged, 80 and over
- Alkaloids
- Alzheimer Disease
(drug therapy, psychology)
- Behavior
(drug effects)
- Cholinesterase Inhibitors
(therapeutic use)
- Cognition
(drug effects)
- Double-Blind Method
- Female
- Humans
- Male
- Memory
(drug effects)
- Middle Aged
- Prospective Studies
- Sesquiterpenes
(therapeutic use)
- Tablets
|